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ABSTRACT 
Radioembolisation (RE), with yttrium-90 (90Y) labelled microspheres, is an increasingly common 
treatment method for unresectable liver tumours. The tolerable mean absorbed dose for normal liver (NL) 
tissue is higher in RE than in External Beam Radiation Therapy (EBRT); absorbed dose heterogeneity is 
thought to be one important reason, together with a low absorbed dose rate, but the knowledge of 
microsphere distributions is limited. The aim of this thesis was to describe macroscopic and small-scale 
heterogeneity in the distribution of microspheres and consequently in absorbed dose, and to create a 
hepatic branching artery tree model, able to reproduce normal liver microsphere and absorbed dose 
distributions. Another aim was to develop and evaluate a method for prediction of absorbed dose to the 
surgeon’s hands during liver resection on still radioactive tissues.  
Two patients with marginally resectable cholangiocarcinoma underwent resection, nine days after RE with 
resin SIR-Spheres®. Considering radiation safety, simulation of absorbed dose to surgeon’s hands was 
performed with the software Varskin Mod 2® before surgery and absorbed dose rate measurements were 
done with thermoluminescent dosimeters (TLD) on resected tissue. The macroscopic sphere distribution 
within NL was investigated by gamma well chamber activity measurements on punch biopsies from sliced 
resected tissues and by calculating coefficient of variation (CV) and skewness (SK), in relation to biopsy 
mass. Small-scale heterogeneity in microsphere and absorbed dose distribution was studied by light 
microscopy and subsequent absorbed dose simulations by beta dose point kernel convolution. A branching 
artery tree model was used, to simulate microsphere and absorbed dose distributions. 
Tissue measurements and simulations of absorbed dose to surgeon’s hands showed similar results. The CV 
and SK of activity concentration, by gamma well chamber measurements, decreased rapidly with 
increasing mass and/or mean activity concentration. Aggregations of clusters increased in frequency and 
CV and SK for absorbed dose distribution increased with mean sphere concentration. The branching artery 
tree model was able to resemble the biopsy sphere and absorbed dose distributions.  
Expected absorbed dose to the surgeon’s hands was not alarming, but simulations and measurements of 
surgeon finger absorbed dose are recommended. Decreasing CV and SK for macroscopic distribution 
indicated a heterogeneous pattern larger than the punch biopsy masses investigated. Small-scale sphere 
and absorbed dose heterogeneity both increased with mean sphere concentration. The branching artery tree 
model helps to explain the distribution mechanism better than previous distribution models. The shown 
heterogeneity and the arterial tree model provide knowledge that may be helpful in optimising RE 
treatment, regarding number of injected spheres and activity per sphere. 
Keywords: clusters, dosimetry, heterogeneity, liver, microspheres, radioembolisation, simulations, SIRT, 
surgery, yttrium-90 
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 SAMMANFATTNING PÅ SVENSKA 
Radioembolisering (RE) genomförs på både primära levercancertumörer och 
metastaser där synlig tumörväxt är begränsad till enbart levern. Det 
vanligaste är att RE utförs på tumörer som inte är operabla, ibland med 
förhoppning om att de ska bli det. Metoden går ut på att mikrosfärer 
(diameter c:a 20 - 40 µm) av glas (Theraspheres®) eller härdplast (resin) 
(SIR-Spheres®) förses med radioaktivitet, i form av β-strålaren yttrium-90 
(90Y) och sedan injiceras via leverartären, m h a kateter; mikrosfärerna 
pumpas av det naturliga blodflödet ut till framför allt levertumörerna och i 
begränsad utsträckning ut i normallevervävnaden. Mikrosfärernas storlek gör 
att de fastnar i de små blodkärlen, i tumörområdet och i levervävnaden. 
Medelräckvidden hos β-strålningen (elektronernas räckvidd) är endast 2,5 
mm, vilket gör att bestrålningen begränsas till mikrosfärernas absoluta närhet, 
således främst till tumörvävnaden. Syftet är att tumörvävnaden ska hämmas 
av strålskadorna, samtidigt som angränsande normallevervävnad måste 
skonas från potentiellt livshotande strålskador. 
Denna avhandling syftar till att beskriva hur ökad kunskap om 
stråldosfördelning i normal levervävnad, vid radioembolisering av 
levertumörer, kan bidra till förbättrade behandlingsmetoder och 
patientöverlevnad. De metoder som använts i de studier som avhandlingen 
baseras på är 1) autoradiografier (fotografering med strålningskänslig film) 
på utopererad, radioaktiv tumör- och levervävnad, 2) uppmätning av 
radioaktivitet i ett stort antal mindre vävnadsprover, 3) registrering av enstaka 
mikrosfärer och mikrosfäranhopningar (kluster) genom mikroskopi,  
4) datorsimulering av mikrosfärfördelning i levern, samt 5) datorsimulering 
av stråldosfördelningar m a p nämnda mikrosfärfördelningar.  Förutom detta 
har även stråldoser till fingrarna hos kirurger som opererar patienter med 
vävnader innehållande radioaktiva isotoper simulerats och stråldosmätningar 
gjorts på uttagen vävnad. Mätningar för att bedöma stråldosen till kirurgens 
fingrar stämde väl överens med simuleringar och visade inte alarmerande 
nivåer; försiktighet bör emellertid iakttas, varför simulering och mätning av 
stråldoser rekommenderas inför eventuell operation av RE-patienter.  
Sammanfattningsvis, är tendens till klusterbildning och grad av 
stråldosheterogenitet i levernormalvävnaden större än vad tidigare forskning 
kunnat påvisa. Därigenom erhålls mer detaljerad kunskap om varför levern 
tolererar en högre medeldos från RE än från extern strålterapi. Dessa rön kan 
möjliggöra metodoptimering, exempelvis vid val av totalt antal injicerade 
mikrosfärer och mängden radioaktivitet per mikrosfär. Sammantaget påvisas 
en potential för förbättring av terapeutisk effekt och patientöverlevnad.
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DEFINITIONS IN SHORT 
Arteriole Arterial vessel with inner diameter < 100 µm 
This definition simplifies the cluster 
distribution description in this work. There is 
space for about 10 microspheres per cross-
section in the largest arterioles, by this 
definition 
Artery, small Arterial vessel with inner diameter ≥ 100 µm 
This definition simplifies the description in 
this work 
Cluster,  
small  
2–19 spheres per cluster 
Cluster,  
medium 
20–49 spheres per cluster 
Cluster,  
large 
50–99 spheres per cluster 
Cluster,  
very large 
≥ 100 spheres per cluster 
Heterogeneity,  
large scale 
Resolution on a scale larger than 2 cm. 
Heterogeneity on this scale can be studied by 
external imaging methods. The considerable 
cross-dose between adjacent volumes on this 
scale is restricted to within a few millimeters 
at the sub-volume edges. 
Heterogeneity,  
macroscopic scale 
Resolution on a scale of 2.5–20 mm (equal to 
or longer than mean range of 90Y beta dose 
point kernel). Structural heterogeneity in 
activity concentration cannot be effectively 
homogenised by cross-fire effects on a larger 
scale than this. 
ix 
 
Heterogeneity,  
small scale 
Resolution on a scale of 1-2.4 mm (shorter 
than mean range of 90Y beta dose point 
kernel). Regular variation on this scale or 
smaller will be more or less homogenised by 
cross-fire. Small-scale heterogeneity is 
interesting from a radiobiological perspective 
if the variation within a small volume is large 
enough to create absorbed dose gradients 
which are not homogenised, e.g. in presence 
of clusters. 
Heterogeneity,  
microscopic scale 
Resolution on a scale < 1 mm. As the 
absorbed dose gradient is very strong close to 
deposits of microspheres, structural 
microscopic heterogeneity is expected to be 
present for isolated spheres. The cross-dose, 
i.e. cross-fire homogenisation effects between 
adjacent volumes, containing microspheres, 
will however be strong on this scale. 
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1 INTRODUCTION 
The liver is the most commonly affected organ by metastatic disease 
(Kuvshinoff and Fong 2007). It has been expected that up to 25% of all 
cancer patients will, sooner or later, develop hepatic metastases (Van de 
Wiele et al. 2012). Unfortunately, a minority of these patients are amenable 
to surgery, the only potentially curative treatment among those with 
colorectal metastases (Kuvshinoff and Fong 2007).        
In a global perspective, primary hepatic cancer, mostly hepatocellular 
carcinoma (HCC), but also cholangiocarcinoma, is the second (men) and 
sixth (women) most common cause of cancer-related death, due to its high 
incidence in developing countries and low curability. Contributing factors to 
HCC are, mainly, chronic hepatitis (Type B and C), in developing countries. 
In developed countries, the causes are more related to alcohol-related 
cirrhosis and obesity-related fatty livers. A high incidence of 
cholangiocarcinoma, in Eastern Asia, is associated with liver fluke, but this 
cancer type is otherwise relatively rare (Jemal et al. 2011). 
Surgery, and thus potential to cure, is possible only for a small minority of all 
primary and metastatic intrahepatic tumours. The options for prolonged 
survival are chemotherapy (Aljiffry, Walsh and Molinari 2009, Okada 1998, 
Lam et al. 2012) external beam radiation therapy (EBRT) (Fuss et al. 2004, 
Chen et al. 2010), including stereotactic (SBRT) (Jung et al. 2013, Mendez 
Romero et al. 2006) and intensity-modulated (IMRT) (Fuss et al. 2004) 
procedures, various ablation techniques (Kim et al. 2011, Minami and Kudo 
2011) and different endovascular procedures; i.e. bland embolisation (Rand et 
al. 2005), transarterial chemoembolisation (TACE) (Llovet et al. 2002) and, 
the subject of this thesis, radioembolisation (RE) (Salem and Lewandowski 
2013), also referred to as Selective Internal Radiation Therapy (SIRT) (Lau et 
al. 1998).  
Standard EBRT is not very efficient, considering the high incidence of 
Radiation-induced liver disease (RILD), when optimising the absorbed dose 
necessary to obtain tumour response (Ingold et al. 1965, Fuss et al. 2004), 
albeit the results are improving, with modern EBRT techniques, mentioned 
above. Radioembolisation, on the other hand, seems to be a promising 
alternative, with low risk of toxicity (Riaz, Awais and Salem 2014), as 
compared to other palliative and, potentially, down-staging (Lau et al. 1998) 
methods mentioned above. Some reports are showing comparable (Kooby et 
al. 2010, Salem et al. 2010, Lance et al. 2011) and other better therapeutic 
outcome for RE (Salem et al. 2011, Lewandowski et al. 2009), as compared 
Small-Scale Absorbed Dose Modelling in Selective Internal Radiation Therapy 
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to TACE, regarding time to T progression and risk of liver toxicity. This is 
interesting as TACE is often considered the standard treatment for HCC, in 
case of intermediate (stage B) disease (Bruix and Sherman 2011). A 
combination of RE and systemic chemotherapy has also shown promising 
results (Chua et al. 2011). 
The pathophysiological background for liver RE and TACE is the dual blood 
supply of the liver, i.e. 1) the low-pressure hepatic portal venous system 
draining the guts and 2) the high-pressure arterial system of oxygenated 
blood, both ending in the sinusoids (capillaries) and drained by the central 
vein (Figure 1). The liver parenchyma obtains only ¼ of its blood supply 
from the artery and the rest from the portal system, while the tumors depend 
almost exclusively (> 80%) on the arterial system (Kennedy et al. 2004). The 
background for this is not clear, but may be related to the increased 
interstitial fluid pressure of tumours causing a collapse of low-pressure 
vessels. By injecting the microspheres into the artery, the tumour-to-normal 
tissue activity concentration ratio (TNC) will thus typically be about 4 (Lau 
et al. 1998), but could at instances be as high as 25, for HCC tumours (Ho et 
al. 1998). TNC < 2, due to poor tumour vascularisation, is a contraindicator 
for RE (Lau et al. 2012), as the therapeutic index is too low (See section 
1.5.1). 
With three patients planned for neo-adjuvant therapy, including SIRT 
followed by surgery, at The Sahlgrenska University hospital, there was an 
opportunity to investigate the microsphere distribution in resected normal 
liver (NL) tissue. Generalisation of the results may be assumed, since the 
healthy liver tissue tends to be structurally similar for different individuals 
(see section 1.1.1). Contrary to normal liver, the structure, not least the 
vascular, of tumour tissues is extremely heterogenous, even within single 
tumour lesions. The focus of this work was on the normal liver tissue, to 
explore the background of the seemingly higher radiotolerance to internal 
radiation compared to EBRT. For this reason, this thesis is focused on the 
gathering of more information on the absorbed dose distribution in liver, 
following radioembolisation. Such information is crucial for the 
improvement of technical aspects of the treatment method and thereby an 
improved survival for these patients. In order to acquire this information, 
both computer simulations, as well as different kind of measurements were 
applied (see Patients and Methods). 
Furthermore, a secondary focus, within the scope of this thesis, was to 
perform simulations of absorbed dose rate to the surgeons before resection 
procedure, as well as absorbed dose measurements on resected tissue, in 
order to validate the method (see Patients and Methods).  
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1.1 Radiobiology and sphere distribution 
In comparison to EBRT (See section 1.4.3), information on the radiation 
field, both within tumour and NL tissue, is limited in RE treatments. The 
treatment is simulated (see section 1.5.1) with an injection of technetium-
99m-labelled macro-aggregated albumin (99mTc-MAA), followed by 
SPECT/CT (Single-Photon Emission Computed Tomography / Computed 
Tomography) imaging on the 140 keV gamma-radiation emitted by 99mTc. 
Several studies (see section 1.5.4) have shown that the actual distribution of 
the therapeutic agent, i.e. 90Y-labelled microspheres, does not coincide well 
with simulations. Another challenge is the dependence on imaging per se; the 
distribution of microspheres could be evaluated post-therapeutically, with 
bremsstrahlung SPECT/CT and/or PET/CT (Positron Emission Tomography 
/ CT). However, such non-invasive imaging methods are able to show only 
large-scale (> 2 cm) variations in 90Y-distribution (see section 1.5.2). 
1.1.1 Representativeness 
Tumour tissue representativeness 
Although the focus of this work is not on tumour tissue, some aspects making 
predictions for sphere distribution and thus absorbed doses will be briefly 
outlined. 
The variation in morphology, considering tumour growth, is dependent on 
many parameters. In comparison to the highly organised normal vessels, the 
tumour vasculature is chaotic, with excessive branching and shunts, causing a 
high variability and unpredictability in blood flow (Carmeliet and Jain 2000, 
Tveit et al. 1987). 
The vascular sprouting and growth towards a small tumour is radially 
organised, directed against the concentration gradient of the Vascular 
Endothelial Growth Factor (VEGF) (Ferrara, Gerber and LeCouter 2003). 
When entering the tumour tissue, the gradient of VEGF no longer exists, 
resulting in a haphazard vascular architecture with connections between 
immature capillaries with a poor and unpredictable blood flow. In larger 
tumours, an increasing interstitial fluid pressure will completely shut-down 
the perfusion in low-pressure vessels by vascular collapse. Furthermore, 
when considering tumour size, the variation in tumour characteristics, 
increases with volume, as larger tumours are more dependent on 
vascularisation (Milross et al. 1997, Lagerlöf, Kindblom and Bernhardt 
2014). As larger tumours tend to suffer from insufficient vascularisation, a 
larger fraction of the central parts may suffer from hypoxia, leading both to 
potential regions of cell death (necrosis) and individual cells with hypoxia, 
Jonas Högberg 
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making them less sensitive to radiation (Kennedy et al. 2004). The 
combination of vascularisation characteristics, affecting the microsphere 
distribution, the fraction of necrotic and low-sensitive tissue, and how these 
tissue types are distributed geometrically, is thus unique for and within each 
lesion. The tendencies are correlated with tumour types (Leith et al. 1994) 
and size; however, as both size and individual characteristics of tumours 
differ, each patient is unique. 
Thus great caution is needed in generalising data from a few or even many 
tumours (i.e. patients). In order to obtain fairly generalisable data, strict 
patient categorisation, based on tumour type and narrow tumour volume 
intervals, as well as other clinically important parameters, is necessary. Such 
categorisation requires large patient groups, in order to obtain large enough 
samples reflecting each category. Retrospective gathering of sufficient data, 
thus often requires multi-centre cooperation, with potential for inclusion-bias 
and lacking transparency for inter-centre methodologic differences and skills 
(Kennedy et al. 2009).  
Normal liver tissue representativeness 
Even though there is evidence of inter-individual, geometric, variation 
(Koops et al. 2004, Song et al. 2010) in the macroscopic artery structure of 
healthy liver tissue, it is obvious that liver parenchyma and its vascularisation 
is governed by genetic, organising rules (Carmeliet and Jain 2000), making 
different human livers resemble each other. With respect to microspheres, the 
distribution of the finest structures of the artery is crucial. The structure and 
function of the subunits of the liver differs between mammalian species, such 
as rats, pigs and humans, but within each species, e.g. humans, the 
characteristics are more constant. (Debbaut et al. 2014, Lamers et al. 1989, 
Crawford et al. 1998, Rappaport 1973, Rappaport et al. 1954, Teutsch 2005).  
As there are large intra-individual variations (Debbaut et al. 2014) in the size 
and distribution of the small units (i.e. liver lobules), as well as in the size 
and distribution of liver vessels, it could be expected that the same kind of 
variation exists in all healthy human livers. The hepatic arterial system 
constitutes 19 – 21 artery generations (Walrand et al. 2014a, Debbaut et al. 
2014), each generation with individual mean diameter as well as coefficient 
of variation (CV) for the diameter. If the mean variation within individuals 
(mean of all CVs), throughout different artery generations, is larger than the  
differences between individuals, concerning corresponding mean diameters, a 
large enough sample from one patient could be considered fairly 
representative for a patient population, even though some fractions of the 
distributions may not overlap between different individuals. The inter-
individual similarities can be considered more striking than the differences, at 
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least on a microscopic level, as reported by Crawford et al. (Crawford et al. 
1998), in comparing biopsies from 16 different patients. Given the 
supposedly genetically organised, albeit heterogenic and semi-randomised, 
fractal geometry principles ruling parenchyma and, probably, vessel structure 
(Crawford et al. 1998, Khokha, Landini and Iannaccone 1994), biopsies from 
healthy liver parenchyma ought to be reasonably representative, concerning 
the dynamic blood flow characteristics in arteries. 
1.2 Pre-clinical experience regarding 
microsphere distributions 
Distribution characteristics, regarding microsphere dimensions and number 
of injected spheres, were studied by Meade et al (Meade et al. 1987). They 
investigated how the distribution of microspheres, injected into rat livers, 
implanted with salivary adenocarcinoma tumour, varied with sphere size. The 
number of spheres injected was higher for smaller spheres. The reason for 
this was the aim for uniform sphere distributions in NL, while obtaining the 
highest TNC possible; they hypothesised that a relatively large number of the 
smallest spheres was needed, in order to obtain the same uniformity as for 
larger spheres. Comparing spheres of diameter 15, 32.5 and 50 µm, they 
found the 15 and 32.5 µm spheres to cause similar ratios (TNC 3.18 vs. 3.21) 
and higher than the 50 µm spheres (TNC 0.88). The CV for the distributions 
in NL decreased with sphere size, i.e. the distribution was more 
homogeneous for the larger spheres. It is notable, though, that the spheres 
were injected with ratios of 40:4:1 for 15, 32.5 and 50 µm, respectively. The 
tumour diameters varied from 4 to 10 mm, which corresponds to volumes of 
less than 0.6 cm3 per tumour. Given the expected NL volume of about 12 cm3 
(Qin et al. 1990) and two tumours (one in each NL lobe), the tumour volumes 
would constitute  less than 10% of NL volume. This means that the 
concentration ratios in NL would still be about 30:3:1, comparing the three 
sphere diameters. Care is therefore needed before concluding that the 
difference in CV for the NL distributions depends on size alone; it is possible 
that the CV dependence is explained by either sphere size, NL concentration 
or both.  
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1.3 Microsphere characteristics 
1.3.1 Radionuclide properties 
Yttrium-90 (90Y) is a radioactive isotope of the rare-earth element yttrium 
(atomic number 39, stable isotope 89Y). 90Y decays, with half-life (T1/2) 2.67 
days, to stable Zirconium-90 (90Zr) (atomic number 40) almost exclusively by 
β- decay, resulting in the emission of a β-particle (electron), with a 
stochastically determined kinetic energy, within the nuclide-specific β-energy 
continuum. The 90Y β-spectrum is relatively high-energetic, compared to 
most other β-emitters (Kassis and Adelstein 2005); the maximum and mean 
energies are 2.28 MeV and 0.934 MeV, respectively. The maximum and 
mean ranges of the β-particles (considering energy deposition distribution as 
described by the 90Y beta dose point kernel) are 11 mm and 2.5 mm, 
respectively, in soft human tissue (Gulec et al. 2010) and the absorbed dose 
in relation to a homogeneous activity concentration, assuming charged 
particle equilibrium, is 49.8 Gy GBq-1 kg-1 (Gulec et al. 2007). The CSDA 
range for the mean energy, 0.934 MeV, is 4.1 mm (Cremonesi et al. 2006). 
There is also a small probability (32×10-6) of an alternative decay process, by 
internal electron & positron (e- & e+) pair production, by which 90Y decays to 
the excited state of 90Zr. The annihilation process of the emitted positrons can 
thus be examined with PET (Lhommel et al. 2009) (see section 1.5.2). 
1.3.2 Microsphere types 
Spheres labelled with 90Y are manufactured as Theraspheres® by BTG, 
Ontario, Canada, (glass spheres) and as SIR-Spheres®, by SIRTeX Medical 
Limited, Sydney, Australia, (resin spheres). The three main physical 
differences between glass and resin spheres, potentially making the 
distribution characteristics type-specific, are shown in Table 1.  
The mean diameters do not differ extensively (Meade et al. 1987), but the 
glass spheres have a higher density and are therefore expected to be less 
compatible with the blood flow (higher aggregation probability) (Ho et al. 
1998) and less comparable to the protein-based pre-therapeutic imaging 
particles (99mTc-MAA). Resin spheres, on the other hand, are more similar to 
protein, in density. The much higher specific activity, of glass- compared to 
resin spheres, shown in Table 1, is, however, compensated for, by a higher 
number of injected resin spheres vs. glass spheres. 
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Table 1. Comparison of reported physical characteristics for glass and resin 
spheres (Nelson, Vause and Koropova 2008, Cremonesi et al. 2014, Vente et 
al. 2009) 
 
 
Type 
 
Density 
(g/ml) 
Diameter (µm)  
Activity/sphere 
(Bq) Mean Standard 
deviation 
Span 
Glass 3.3 25 Not specified 20 – 30 2500 
Resin 1.6 32.5 2.5 20 – 60 50 
 
The number of glass spheres injected, per patient, is similar to the injected 
number of 99mTc-MAA particles at pre-therapeutic imaging, but the number 
of resin spheres injected is much higher. The high number of resin spheres 
therefore increases the tendency of aggregation and embolisation, although 
the spheres are more similar to the MAA particles. As both sphere types 
show promising therapeutic outcome, the two brands probably rely on 
different methodology, regarding distribution characteristics (see section 
1.4.4). 
1.4 Clinical background 
1.4.1 Tumour response 
As mentioned in the introduction, RE is continuously increasing as an 
adjuvant and alternative treatment for unresectable primary liver tumours and 
metastases confined to the liver. Albeit with slightly different physical 
properties (see section 1.4.2), both resin and glass spheres are successful in 
achieving a high TNC and are showing tumour response and prolonged 
patient survival outcomes, comparable to or higher than chemotherapy, not 
the least when RE and chemotherapy are combined. When treatment is 
successful it sometimes leads to down-staging (Lau et al. 1998) and enables 
surgery (see Introduction).  
1.4.2 Normal tissue complications 
There is still little knowledge about the radiation tolerance of NL tissue in 
RE, as it is hard to distinguish between administration-related and 
radiobiological complications (Kennedy et al. 2009) and furthermore, 
information about NL tissue absorbed dose is seldom available, especially for 
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glass spheres (Cremonesi et al. 2014). It is notable that the number of 
microspheres injected differs substantially, with a factor of 25 – 50 times 
higher for resin as compared to glass spheres. The different number of 
spheres per injection is reached by allocation of different activity per 
microsphere. It seems as if both tumours and NL have a higher tolerance for 
glass spheres, as higher MAD to tumour is needed for response, but also with 
seemingly less NL complications (Spreafico et al. 2014). It is hard to do 
conclusive comparisons, based on available clinical data, however, as 
determination of TNC (and thus the determination of administered absorbed 
dose to NL tissue) is not always considered necessary and, when performed 
post-therapeutically, the methods differ. (Cremonesi et al. 2014, Kao et al. 
2011a, Riaz et al. 2011).  
If the above assumption, about higher tolerance for glass spheres, is valid, it 
may be that this phenomenon depends on a less uniform absorbed dose 
distribution (see section 1.6) in both tumour and NL, for glass spheres 
(Walrand et al. 2014a). If the uniformity of absorbed dose, within NL, is 
more similar for the two sphere types than expected, however, there is an 
alternative possibility, that the higher incidence of complications for resin 
spheres depends more on administration failure, than on a more uniform 
absorbed dose distribution within NL, in general. It is important to identify 
patients with unfavourable vascularisation in tumour, as the resulting TNC 
otherwise may be too low, with a consecutive risk of a too high absorbed 
dose to NL (Kao et al. 2012). In that case, it is even possible that many 
complication-free patients may have been undertreated, as caution with the 
amount of administered activity may be influenced by maltreatments, due to 
lack of clinical information. 
1.4.3 NTCP & TCP optimisation 
A constant challenge in radiation therapy is the demand of minimising the 
normal tissue complication probability (NTCP) (Walrand et al. 2014b, Chiesa 
et al. 2012, Strigari et al. 2010), while maximising the tumour control 
probability (TCP), in order to kill the largest possible fraction of the tumour 
volume. The risk of liver failure in EBRT is calculated to be very low (< 5% 
within 5 years; TD5/5), if the MAD in the semi-homogeneous (i.e slow dose 
gradients present within major parts of NL) radiation field is kept below 30 
Gy, for the whole liver treatment, and below 40 - 50 Gy in a treatment where 
only 1/3 of the NL is within the radiation field, (Milano, Constine and 
Okunieff 2007, Emami et al. 1991, Pan et al. 2010). The advantage in the 
treatment of the liver, being an organ with a repetitive functional structure 
(i.e. a parallel organ) (Källman, Ågren and Brahme 1992), is that a high 
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absorbed dose (up to 90 Gy) to outskirts of the NL does not imply failure of 
the entire organ (Pan et al. 2010, Dawson et al. 2002). 
There are several pit-falls present in comparing EBRT to RE; the radiation 
field in EBRT could be considered semi-homogeneous, in comparison to the 
non-uniform field that may be present within a microsphere distribution. In 
an ideal situation, with perfect knowledge of the radiation field, it would be 
tempting to compare dose-volume histograms from EBRT with RE. Caution 
is needed in doing such comparisons, though, as the spatial distribution is 
expected to be different, with slow-gradient fields in EBRT and a high 
number of distributed point sources in RE. Not yet considering the range of 
the radiation in RE and thus the extent of crossfire, it is still reasonable to 
think that tissue structures distributed close to lodging sites of microspheres 
are expected to suffer more from these points sources than tissue structures 
distributed farther from such sites. 
1.4.4 Microsphere distribution heterogeneity 
As mentioned in section 1.4.2, the number of microspheres injected seems to 
have a high impact on the level of resulting heterogeneity in both sphere and 
absorbed dose distributions. The ideal treatment would of course be limited 
to the tumour tissue (infinite TNC). This is not possible in practice, but an 
important aim is to achieve a high TNC and a low absorbed dose to NL. 
Typically, the TNC is within the span of 2 – 7 for metastases (e.g. colorectal 
cancers), but the variation tends to be even higher in treatment of HCC (Ho et 
al. 1997).  
Particle range considerations 
When the distribution of the therapeutic radionuclide is expected to be fairly 
homogeneous, and/or when the tumours are considered small, a radionuclide 
with a low (α-emitters, range < 100 µm) or medium range (low energy β-
emitters, mean range < 1 mm) is the best choice, in order to obtain a low 
absorbed dose to healthy tissue, surrounding the tumour. When the 
radionuclide distribution is expected to be heterogeneous (due to tumour size 
or heterogenic structure, e.g. for unresectable liver tumours), it is preferable 
to use a radionuclide that is able to homogenise the heterogeneous 
distribution, thereby obtaining a more uniform absorbed dose distribution, 
thanks to so called crossdose by crossfire effects (Kassis and Adelstein 
2005). However, the mean range of the β-radiation is only 2.5 mm (see 
section 1.3.1). As mentioned in section 1.6, the absorbed dose drops of by a 
factor 100 in just 1 mm (Gulec et al. 2010). Given that a cube has eight 
corners, the centre in a unit cube in a homogeneous single sphere pattern of 
unit size 2.5 mm will receive the major absorbed dose contribution from 
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eight close spheres, the sum being only a few percent of the self-absorbed 
dose for a 0.5×0.5×0.5 mm3 voxel, containing a microsphere.  The total 
absorbed dose contribution from the next shell of 64 - 8 = 56 spheres is also 
only a few percent; the total contribution from the next shell of 216 - 64 = 
152 spheres is even less, as well as from the fourth shell of 512 – 216 = 296 
spheres. The maximum range of 11 mm means that a maximum of four shells 
will influence the absorbed dose. As the contribution from each of these 
shells is only a few percent, it is fair to assume that heterogeneity on a scale 
of 2.5 mm (or even smaller) will not be homogenised by cross-fire. A cube 
with side 2.5 mm has a mass of 2.5×2.5×2.5 = 16 mg, assuming density 1.0 g 
cm-1.  
Normal liver parenchyma vs. tumour tissue 
Heterogeneity in absorbed dose distribution, following RE, causing cold 
spots of low absorbed dose within tumour tissue will not be beneficial from a 
tumour killing perspective. Within NL tissue, on the other hand, such cold 
spots will increase the probability of parenchyma survival. As mentioned in 
section 1.1.1, the characteristics of tumour tissue and NL parenchyma, 
including vascularisation, are very different. NL parenchyma, being governed 
by fractal geometry principles by genetic rules, is expected to possess higher 
levels of organised complexity, regularity and predictability than tumour 
tissue, the latter being more chaotic (and thus with a less generalisable 
character).  
The implication of this is that, even though heterogeneities are found both 
within NL tissue and tumour tissue, the heterogeneity within the two tissue 
types could not be expected to be similar, even though it is not impossible. 
Even in the therapeutically non-ideal situation of a TNC close to 1 (similar 
microsphere concentration in both tissues), the intrinsic microsphere 
distributions could not be assumed to be similar, comparing the two tissue 
types. 
In case of a sufficiently high TNC, a fairly uniform absorbed dose 
distribution (due to a high sphere concentration) within tumour tissue may 
still be accompanied by substantial absorbed dose non-uniformity within NL 
tissue, which would be favourable, from a therapeutic, radiobiological point 
of view. On the other hand, it is possible that a non-uniform absorbed dose 
distribution in tumour will be accompanied by a quasi-uniform absorbed dose 
distribution in NL. The latter case would of course not be optimal from a 
therapeutic point of view, unless the TNC is very high.  
Therefore, important aims are to investigate i) the degree of heterogeneity in 
the NL microsphere distribution, ii) the absorbed dose distribution within NL, 
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following RE therapy, and iii) the relationship between these non-
uniformities and the local mean microsphere concentration (See Aims).    
Locally absorbed dose in normal liver tissue  
As microspheres are lodging in the smaller arteries and arterioles in the portal 
tracts (PT), (also called portal triads, referring to their idealised structure, as 
illustrated in Figure 1), the absorbed dose distribution for PT could be 
expected to have a higher MAD than the total parenchyma volume. Very few 
spheres can pass through the capillaries over to the central vein, within NL, 
and the total volume of central veins is thus expected to receive an even 
lower MAD (Gulec et al. 2010, Walrand et al. 2014a).   
Cluster gatherings and small-scale dose distributions 
The studies of small-scale microsphere distribution in NL tissue are few and 
limited regarding patient specific volume. Roberson et al (Roberson et al. 
1992) studied and did dose simulations based on a small biopsy sample of 
rabbit NL and tumour tissue being injected with microspheres (polystyrene 
spheres, diameter 27 µm) and found a large variance in absorbed dose 
distribution in both tumour and NL. They reported cluster maximum sizes of 
8 for NL and 13 for tumour and, furthermore, that the total relative variation 
(i.e. heterogeneity) in microsphere distribution was larger in normal than in 
tumour tissue. They admitted the need for a larger sample size in order to 
make conclusions about total NL distribution.  
Pillai et al (Pillai et al. 1991) found even larger clusters (maximum sizes > 25 
spheres per cluster) in rabbit NL and tumour tissue, using the same 
polystyrene microsphere type. For NL concentrations of 4.7 and 6.6 
spheres/mg (corresponding to 12 and 17 Gy regions for resin spheres vs. 300-
600 and 400-800 Gy regions for glass spheres), they found microsphere mean 
cluster sizes of 3.6 and 4.4 spheres per cluster, respectively; the clusters 
tended to be larger in tumour tissue, but primarily explained by large TNCs, 
as a TNC of 6 resulted in a similar mean cluster size as compared to NL and a 
TNC of 10 resulted in less than a doubled (factor 1.8) tumour mean cluster 
size. Given the high TNC in combination with a not very much larger mean 
cluster size for tumour tissue, the mean distance between clusters was four 
times higher in NL tissue (9.3 mm in NL vs. 2.5 mm in tumour), resulting in 
an expectedly more non-uniform D distribution in NL as compared to 
tumour, if using radiolabelling by β-emitters. 
In a human study by Burton et al (Burton et al. 1989), one or a few biopsies 
of masses 1–10 g were collected from 9 patients and were sectioned into 2-51 
0.1–0.2 mm sections per patient; the activity was then detected in a liquid 
scintillator. They found a large intra-biopic variance of the activity, described 
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with the coefficient of variation (CV); the variation between individuals was 
also high, however, as the CVs varied between patients: 0.31 to 1.6 in NL 
and 0.19 to 0.98 in tumour. Analysing some of their presented data, the CVs 
are found to have a negative correlation with absorbed dose (-0.4 for tumour 
and -0.5 for NL). The total volume investigated for each patient was small, 
however; it is possible that there is a large macroscopic variation throughout 
the liver, but the correlations suggests that there may be a tendency of 
decreasing microsphere heterogeneity with increasing MAD for both NL and 
tumour. As no three-dimensional small-scale investigation was made, little 
can be said about the distribution within individual thin sections from this 
study.  
Fox et al (Fox et al. 1991) analysed a small volume of NL tissue and found a 
highly heterogeneous absorbed dose pattern. 
There have been some reports (Kennedy et al. 2004, Campbell, Bailey and 
Burton 2000) on cluster gatherings in tumour tissue, studied in explanted 
tissue, treated some time before dissection. Kennedy et al reported, after 
dissection of four explanted livers, that both glass and resin microspheres 
caused high MAD regions, with heterogeneous microsphere aggregation 
patterns. Not much information is reported about intentions to track clusters 
in three dimensions; the clusters found for resin spheres were however larger 
(up to 20 spheres) compared to clusters of glass spheres (up to 4 spheres), 
probably explained by the 50 times lower activity per resin sphere as 
compared to glass spheres, and thus a higher total number of injected resin 
spheres, as the total injected activities were similar (3 GBq for resin- vs. 5 
GBq for glass spheres). The TNCs were considerably higher for glass 
spheres, but the clinical value of this comparison is questionable, given the 
low number of patients (low representativeness for tumour tissue, as 
mentioned in section 1.1.1) and the tumour / sphere type specific 
relationship; the two patients receiving resin sphere treatment suffered colon 
metastases and the two glass sphere patients suffered HCC.  
It is still notable that higher TNC for glass spheres (both TNCs > 6) did not 
result in a higher fraction of tumour volume destruction (detected as necrosis 
or fibrosis) than for resin spheres (both TNCs < 3). The reason for this may 
be coincidental, but it may also be that the radiation field, caused by glass 
spheres, tends to be more heterogeneous, given the much lower number of 
glass, as compared to resin spheres, and the stronger absorbed dose gradient 
in the vicinity of glass spheres, caused by higher activity per sphere. 
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1.4.5 BED vs. absorbed dose 
Biological Effective Dose (BED), explained by the linear-quadratic (LQ) 
absorbed dose effect formalism (Dale 1985), is a common term within EBRT 
(Dale and Jones 2007), in order to account for absorbed dose rate and 
absorbed dose fractioning effects. Cremonesi et al (Cremonesi et al. 2008) 
applied the BED formalism on RE, when investigating the potential benefit 
of multi-cycle treatment in RE. They showed that BED to NL could be kept 
constant, independent of number of treatments (1 RE to 1/1 liver; 2 REs to 
1/2 liver or 3 REs to of 1/3 liver) as absorbed dose increased slightly for NL 
and both absorbed dose and (more importantly) BED increased for tumour, 
with expected better outcome for RE therapy. Other authors (Strigari et al. 
2010) have also opted to explain clinical outcome of RE by NTCP and TCP 
models, including BED formalism. Non-uniformity is also treated by 
inclusion of the concept of Equivalent uniform BED (EUBED); it is notable, 
however, that different end points are compared, as the critical tissue in 
EBRT (with quasi-homogeneous D distribution in NL) is the central vein 
(risk for RILD) and in RE the hepatic arteries of the PT (risk for RE-induced 
liver disease, REILD) (Cremonesi et al. 2014). The reason for this difference 
is the mentioned lodging of microspheres within the arteries and arterioles in 
the PT, and the consequences of this for the microscopic absorbed dose 
distribution (See section 1.6).  
1.5 Imaging 
In any radionuclide therapy, information about the patient-specific pre-
therapeutic clinical situation is crucial, for a determination to be made on 
whether the patient complies with the prerequisites for the suggested therapy 
or not. In RE therapy, it is important to identify any considerable risk for 
extensive shunting of microspheres to the lungs, gut, pancreas etc., as this 
may cause under-treatment of tumour tissue, as well as severe radiation-
induced complications in mentioned organs (Goin et al. 2005, Yip et al. 2004, 
Leung et al. 1995, Hamami et al. 2009). One way of gathering this 
information is to simulate treatment with 99mTc-MAA imaging (see section 
1.5.1). Furthermore, such imaging can provide additional information about 
the expected TNC and thus the probability for tumour response by the 
planned treatment. It is also of clinical value to gather post-therapeutic 
information about the actual distribution of spheres and thereby the achieved 
radiation field in both tumour and NL tissue, in order to find possible 
relationships between distribution characteristics (e.g. TNC) and the outcome 
of the treatment (i.e. tumour response and patient population survival). Two 
possible post-therapeutic imaging techniques are i) SPECT (Ahmadzadehfar 
et al. 2011a) (see section 1.5.2), i.e. imaging of bremsstrahlung, emitted when 
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the β-radiation is losing kinetic energy within tumour and NL tissue, and ii) 
PET, by positron-electron pair annihilation (see section 1.3.1 and 1.5.2), 
caused by the, for 90Y, very rare decay process of internal pair production 
(Lhommel et al. 2009). Both SPECT and PET are combined with CT or MRI 
for optimal anatomic information. 
1.5.1 Pre-therapeutic 99mTc treatment simulation 
In order for the risk of extra-hepatic complications to be minimised, pre-
therapeutic simulations of therapy are vital. As 95% of the MAA particles 
have diameters of 10 to 100 µm (Gandhi et al. 2013) and more typically 15 to 
30 µm (Gulec et al. 2007), the size of MAA is similar to that of both 
microsphere types (20 to 40 µm). 
Planar imaging 
Pre-therapeutic planar imaging of the 99mTc-MAA distribution is performed 
in order to rule out the risk of too much of the therapeutic activity ending up 
in the lungs (O'Doherty, Scuffham and Hinton 2011). In case of lung 
shunting (LS) of 10 – 20%, the total injected therapeutic activity of 90Y 
spheres is lowered by 20 – 40%, for resin spheres, whereas therapy is avoided 
if LS > 20%; for glass spheres no adaption is made, but therapy is avoided if 
LS > 10% (Cremonesi et al. 2014).  
SPECT/CT 
In order for three-dimensional information about the expected distribution of 
therapeutic spheres to be gathered, planar imaging of 99mTc-MAA is often 
complemented by subsequent SPECT/CT of the NL and tumour region 
(Hamami et al. 2009). Thereby the TNC, and absorbed dose to tumour and 
NL tissue, may be determined (Ho et al. 1997, Gulec et al. 2007). A mean 
TNC < 2 is considered a contra indication for therapy (Kao et al. 2013a, Lau 
et al. 2012, Lau et al. 1998), as the achievable tumour absorbed dose often is 
too low at this level (See Introduction).   
1.5.2 Post-therapeutic imaging 
90Y bremsstrahlung SPECT 
As the therapeutic radionuclide 90Y emits high energy β-radiation, the energy 
loss of the β-radiation, in its interaction with human tissue, gives rise to a 
bremsstrahlung emission spectrum. These photons can be detected by 
SPECT, even though the wide energy spectrum implies new challenges, not 
present in quasi-mono-energetic 99mTc γ-radiation imaging; in order to 
achieve high enough signal, one may use a wide energy window, typically 55 
– 285 keV (Shen et al. 1994b, Knesaurek et al. 2010, Ahmadzadehfar et al. 
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2011b). The most energetic bremsstrahlung photons, together with scattered 
ones, will cause too much collimator septal penetration, blurring the entire 
image, with use of a Low-Energy (LE) collimator. The use of a Medium-
Energy (ME) or a High-Energy (HE) collimator (Knesaurek et al. 2010, 
Ahmadzadehfar et al. 2011b, Elschot et al. 2011) and filtering (Shen, 
DeNardo and DeNardo 1994a) techniques may enable imaging with a fair 
sensitivity, i.e. signal-to-background ratio (SBR), and spatial resolution (Shen 
et al. 1994b) (See also Section 1.5.5). 
90Y PET 
Thanks to the low, but considerable, probability of internal pair production, 
by the alternative decay process (see section 1.3.1), high enough 90Y activity 
concentration in tissue shortly after therapy enables PET/CT or PET/MRI. 
Sufficiently high resolution and signal-to-noise ratio (S/N) are obtainable 
with conventional time-of-flight scanning, by small adjustments in scanning 
and image reconstruction parameters (Lhommel et al. 2009, Kao et al. 2011b, 
Wissmeyer et al. 2011, Kao et al. 2013b). 
Comparison of post-therapeutic imaging methods 
The spatial resolution is better for 90Y PET (9.3 mm)  (Kao et al. 2013b) than 
for 90Y bremsstrahlung SPECT (11 – 17 mm, depending on body/phantom 
depth of radioactive volume) (Elschot et al. 2011). In order to distinguish 
nearby volumes of similar or different activity, it is more interesting to 
compare contrast recovery coefficients (CRC) and its dependence on activity 
source diameter. A simplified description of CRC is: the ratio of measured 
vs. actual activity concentration ratio, where the activity concentration ratio 
refers to a smaller volume vs. a larger volume surrounding the smaller 
volume. PET has shown better CRC (ideally CRC = 100%) than parallel 
collimator bremsstrahlung SPECT. In a phantom with 10 times higher 
activity concentration in phantom spheres, compared to surrounding liquid, 
the CRCs were: SPECT: 25% vs. PET: 55%, for spheres with diameter 10 
mm; for corresponding 37 mm spheres, the CRCs were: SPECT: 42% vs. 
PET: 89% (Elschot et al. 2013). SPECT is however a competitive alternative, 
considering imaging straightforwardness and cost-effectiveness (Walrand et 
al. 2011) (See also section 1.5.5).  
1.5.3 Correlation of pre-therapeutic imaging and 
clinical outcome 
Even though there are studies showing correlation between pre-therapeutic 
99mTc-MAA-imaging TNC and tumour-response (Gulec et al. 2007, Flamen 
et al. 2008, Kao et al. 2012) there are also reports not able to show such 
correlation (Dhabuwala, Lamerton and Stubbs 2005, Haug et al. 2011). The 
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use of 99mTc-MAA SPECT (in comparison to only planar 99mTc-MAA 
imaging, for shunting examination) is however advisable, from a safety 
perspective, as SPECT is superior in identifying patients with increased risk 
for intra-hepatic or extra-hepatic radiation toxicity (Kao et al. 2013a, 
Ahmadzadehfar et al. 2010, Hamami et al. 2009) (see section 1.5.1).  
1.5.4 Pre- vs. post-therapeutic imaging 
The reason for 99mTc-MAA being a questionable predictor of tumour 
response is in line with reports, showing that i) catheter positioning and ii) 
unique physical properties of MAA may influence the distribution patterns, 
resulting in a poor correlation (Wondergem et al. 2013). Post-therapeutic 
PET (Haug et al. 2011, Kao et al. 2013b) and SPECT (Meyer et al. 2014, 
Ahmadzadehfar et al. 2014) imaging techniques are therefore often better 
indicators of tumour response and risk for complications. Given the actual 
benefits of pre-therapeutic images together with more reliable information 
obtainable by post-therapeutic imaging, the combination of both is highly 
desired.  
1.5.5 Future post-therapeutic imaging methods 
Some studies (Minarik, Sjogreen Gleisner and Ljungberg 2008, Rong et al. 
2012) have shown the potential of improving CRC in bremsstrahlung 
imaging, by applying compensatory kernels for attenuation, scatter and 
collimator-detector effects in the reconstruction algorithm, but these methods 
are not yet clinically available. As PET is a more expensive imaging method 
than SPECT, Walrand et al (Walrand et al. 2011) presented a pinhole 
collimator SPECT system (increased CRC as compared to parallel collimator 
SPECT) as an alternative to PET imaging. 
Another way of improving post-therapeutic imaging properties in RE is the 
use of spheres labelled with nuclides emitting both β- and γ-radiation, e.g.  
Rhenium-188 (188Re) (Nowicki et al. 2014) and Holmium-166 (166Ho) (Smits 
et al. 2012). The obvious advantage is the possibility to use more traditional 
(i.e. narrow energy window) SPECT techniques for post-therapeutic imaging, 
with almost perfect CRC. An additional advantage of 188Re (T1/2: 16.9 h; 
maximum β-energy: 2.12 MeV; γ-energy: 155 keV), over 90Y, is the lower 
cost (90Y is produced by chemical separation from the mother nuclide 90Sr, 
common in fission product waste) (Kodina, Korpusov and Filyanin 2002) and 
higher availability, as 188Re is produced in a generator, that can be set up in a 
hospital radiopharmacy, with the rather long-lived mother nuclide Tungsten-
188 (188W, T1/2: 69 days) (Knapp et al. 1997). 166Ho (T1/2: 26.8 h; maximum 
β-energy: 1.84 MeV; γ-energy: 81 keV) distribution, on the other hand, is 
possible to examine with MRI, since holmium is paramagnetic (van de Maat 
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et al. 2013). 166Ho is also generator-produced, without need to rely on access 
to accelerator or reactor (Uusijärvi et al. 2006). Even though the mentioned 
nuclides have similar energy properties and mean CSDA range (Mean CSDA 
range: 90Y: 4.1 mm; 166Ho: 0.9 mm and 188Re: 3.8 mm), the therapeutic 
properties may still differ and need further clinical evaluations, as the 
absorbed dose rate, being different for the three radionuclides, is an important 
parameter (Hall and Brenner 1992, Cremonesi et al. 2006).  
1.5.6 Imaging limitations 
Low imaging spatial resolution (see section 1.5.2), compared to distribution 
heterogeneity and absorbed dose non-uniformity, makes available non-
invasive imaging methods unable to describe the small-scale absorbed dose 
distribution. Therefore, smaller, but potentially frequent, low absorbed dose 
(“cold”) volumes within NL parenchyma, remain undetected with SPECT 
and PET. Knowledge of such cold volume distributions may be beneficial, 
for the development of a better NTCP model for RE, but methods, 
complementary to external imaging, are needed. 
1.5.7 Small-scale distribution and dosimetry 
Knowledge about small-scale distribution would add another dimension to 
the otherwise large-scaled data bank of absorbed dose distribution. Even 
though investigation of macroscopic and small-scale absorbed dose 
distribution (e.g. biopsy samples from treated patients) is not feasible on a 
regular basis, in-vivo, such knowledge, i.e. increase/decrease of heterogeneity 
with large-scale absorbed dose (the latter available by imaging) would be 
important clinical input. Such knowledge may justify the inclusion of e.g. a 
radiobiological correction factor for heterogeneity, as a function of absorbed 
dose. Increased knowledge of the relationship of microsphere concentration 
and aggregation tendency (cluster formation) may affect the optimisation of 
number of injected spheres and preferred activity per sphere. To provide 
information about small-scale sphere and absorbed dose distributions is one 
main objective of this thesis. 
1.6 Computer models 
Some computer models have been developed for microsphere as well as 
absorbed dose distributions, following RE, on a microscopic, small and 
macroscopic scale. Kennedy et al (Kennedy et al. 2010) developed a model, 
trying to describe the microsphere flow distribution through arterial 
branching nodes (bifurcations). Their model demonstrated that the 
distribution of microspheres, through different daughter vessels, did depend 
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on parameters such as vessel bifurcation geometry, shape of particle inlet 
distribution (uniform vs. parabolic) and pressure boundary conditions. 
Furthermore, authors from the same research team demonstrated, in another 
study (Basciano et al. 2010), that glass and resin spheres are expected to 
distribute in similar ways, despite their difference in physical characteristics. 
Concerning absorbed dose distribution, Gulec et al (Gulec et al. 2010) 
simulated small-scale absorbed dose distribution (Stenvall et al. 2014), by 
Monte Carlo modelling, for various microanatomic structures surrounding 
deposited microspheres. In lack of clinical data, on true sphere distribution 
patterns, a uniform distribution was assumed, within the terminal arterioles of 
the portal triads. This model showed strong absorbed dose gradients; when 
crossfire was ignored, the adjacent PT artery, lodging a sphere, received an 
absorbed dose more than 100 times higher than the absorbed dose received 
by liver parenchyma residing > 1 mm from a sphere. Including cross fire 
effects, the ratio of the absorbed dose to parenchyma vs. to PT was 1:3. The 
consequence of the uniform sphere distribution was a lack of absorbed dose 
variance within the same structural category (e.g. PT), for high sphere 
concentrations, corresponding to resin sphere distributions. For low sphere 
concentrations, corresponding to glass sphere distributions, the ratio of 
absorbed dose to parenchyma vs. to PT varied between 1:1 and 1:5. This was 
due to the number of spheres being lower than the total number of PT, 
leaving only one sphere in every other portal tract. According to this model, a 
lower number of spheres may be beneficial, with a larger fraction of the total 
PT volume receiving a moderate absorbed dose.    
Walrand et al (Walrand et al. 2014a) considered the outcome of the 
mentioned models (Kennedy et al. 2010, Gulec et al. 2010) and constructed 
an extended model, including non-uniform distributions of microspheres and 
absorbed dose. Non-uniformity was obtained by the assignment of uneven 
relative spreading probability throughout the vessel bifurcations of a virtual 
branching artery tree model, with 21 branching nodes. The effect of non-
uniformity was larger for a low number of injected spheres, corresponding to 
typical concentrations for glass sphere RE, as compared to the higher sphere 
concentration for resin spheres. This is in harmony with the hypothesis of a 
higher tolerance for glass as compared to resin spheres, mentioned in section 
1.4.2 and in the above paragraph. They also performed NTCP-modelling, in a 
related study, applying the results from their arterial tree model (Walrand et 
al. 2014b). 
Debbaut et al. (Debbaut et al. 2014) demonstrated, by corrosion casting and 
micro-CT imaging, that the native hepatic artery tree deviates much from an 
idealised dichotomous bifurcation model, in which a parent artery is divided 
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into two daughter arteries; the latter is therefore an overly simplified version 
of a native hepatic artery tree. It is of interest to identify the volume for 
which a dichotomous bifurcation model can accurately simulate microsphere 
deposits and to determine whether such a volume is dependent on 
microsphere concentration. Clinical gains are expected from 
validation/modification of the mentioned branching artery tree model, by 
Walrand et al, with findings of microsphere distributions in dissected NL 
tissue and, if necessary, inclusion of more parameters in a similar model, with 
the possibility to obtain more realistic small-scale as well as macroscopic 
absorbed dose distributions. One clinical gain of a more accurate microsphere 
and absorbed dose distribution model is a subsequently better explanation of 
tolerance and risk of toxicity. Optimisation of number of injected spheres 
(and/or modification of activity per sphere) or variation of other parameters, 
such as sphere diameter, radionuclide, etc., may also become feasible. The 
construction of such a modified arterial tree model is another important 
objective of this thesis.     
1.7 Radiation safety and surgery 
The absorbed dose rate to the hands, for the technologist (at preparation) and 
the physician (at administration) is about 0.7 – 1.0 mSv h-1 (SIRTeX, 2007). 
Each exposure time is, typically, about half an hour, hence not causing any 
serious issues concerning radiation safety. 
Surgery on highly radioactive patients is, however, not a common procedure; 
special caution and awareness are therefore needed. Even though only about 
10% of the radioactivity is left at time of surgery (after 9 days of post-
therapeutic physical decay), it can be expected that the exposure of the 
surgeons hands will be much higher, than for the personnel involved in RE 
administration. There are two main reasons for this, i) direct finger- and palm 
contact (albeit gloves are used) with the radioactive (both tumour and NL) 
tissue and ii) a several times longer exposure time. The absorbed dose limit 
for the extremities and body skin of radiation workers is 500 mSv yr-1 
(Directive 1996). It is crucial to estimate how many (if any) complete 
surgical procedures that can be performed, without the surgeon transcending 
the annual limit. Such estimations are possible with computer simulations 
and could be evaluated with measurements on resected tissue; both methods 
are accounted for in this work. 
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“If you do not know where you are going, any road will get you there” 
 
-Lewis Carroll 
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2 AIMS 
The aims of this thesis can be divided into two main categories. 
2.1 Microsphere and absorbed dose 
distribution characteristics 
Aims regarding distribution parameters were focused on NL tissue.  
1. To describe macroscopic heterogeneity in the distribution of 
microspheres on a therapeutically relevant geometric scale 
considering the range of 90Y β-particles 
2. To study small-scale heterogeneity by the occurrence and 
size of microsphere clusters in relation to biopsy MAD and 
simulate small-scale absorbed dose distributions based on 
mentioned biopsy sphere-cluster distributions 
3. To create a hepatic artery tree model, able to reproduce NL 
microsphere distributions and predict absorbed dose 
distributions 
2.2 Radiation safety during surgery 
To develop and evaluate a method of predicting absorbed dose rate to the 
surgeon’s hands during liver resection on still radioactive RE patients, 
through computer simulations and TLD measurements on resected tumour 
and NL tissue 
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“If I had eight hours to chop down a tree, I would spend six hours 
sharpening my axe” 
 
-Abraham Lincoln 
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3 PATIENTS AND METHODS 
3.1 Patients (I,II,III,IV) 
Two female patients, age 33 (Pt 1) and 62 (Pt 2) years suffered 
cholangiocarcinoma, confined to the liver, but only marginally resectable, 
because of proximity to critical vascular and biliary structures. Both patients 
were selected for neo-adjuvant treatment, with RE, followed by marginal 
resection, aiming for reduced risk of local recurrence at resection margins. 
Pre-study CT investigations revealed that Pt 1 had tumour masses of 770 (left 
lobe) and 180 g (right lobe), with NL tissue of 100 and 1200 g in respective 
lobes; Pt 2 had tumour masses of 37 (left lobe) and 56 g (right lobe), close to 
vena cava, liver veins and PT, with NL of 700 and 1350 g, respectively. 
3.1.1 Pre-therapeutic investigations 
Before RE treatment, the vascular properties of tumour regions were 
examined, in order to assure safe treatment; the patients were investigated by 
selective hepatic artery angiography and artery coiling, followed by infusion 
of 99mTc-MAA. Information about expected therapeutic tumour and NL 
distribution, TNC and the risk for excessive pulmonary shunting could be 
obtained, by planar imaging and SPECT/CT with a GE Millenium VG 
camera (energy window 126-154 keV), with high resolution (HR) collimator. 
The image matrix was 256×256, with voxel size 2.21 mm, resulting in a field 
of view (FOV) of 57×57 cm2. The iterative ordered subset expectation 
maximisation (OSEM) algorithm was used for tomography reconstructions. 
3.1.2 Radioembolisation 
For both patients, the hepatic artery was recannulated for infusion with SIR-
Spheres, two weeks after 99mTc-MAA examinations. Table 2 shows the 
administrated activities and number of spheres injected during less than an 
hour, suspended in 30-40 ml of distilled water. The remaining activity 
concentrations, at the respective days of surgery, are also shown in the table. 
The large-scale distribution of administrated activity was examined by 
bremsstrahlung detection, with the same imaging method and parameters, but 
with another energy window (55-285 keV) and a medium energy (ME) 
collimator. The comparison of 90Y bremsstrahlung and pre-therapeutic 99mTc 
images revealed some large-scale deviations, larger for Pt 1, but with no 
signs of administration failure, such as excessive shunting, for any of the 
patients. 
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Table 2. Injected activities and approximate number of spheres at RE and 
activity concentrations at surgery (9 days post-RE). T means tumour and NL 
normal liver tissue. When numerical values are absent, knowledge of actual 
values is missing.  
 Patient 1 Patient 2 
 
Left 
lobe 
Right 
lobe 
Left 
 lobe 
Right  
lobe 
 T NL T NL T NL T 
Activity 
(GBq) 1.5 - 0.90 - 1.0 - 0.56 
Number of 
spheres 30×10
6 - 18×106 - 20×106 - 12×106 
Activity 
conc. 
(kBq cm-3) 
190 50 140 65 250 64 250 
 
3.1.3 Surgery 
On the ninth day post-RE, the patients were re-admitted for surgery. The 
objective of the resection procedure was removal of macroscopic tumour, 
including a substantial rim of surrounding NL tissue, when possible. 
Dissection was performed with an ultrasonic cavitron aspirator. The resected 
tissue was immediately immersed in isotonic formaldehyde for 48 hours.  
3.2 Surgery radiation exposure (I) 
3.2.1 Simulations 
Simulations of dose rate to fingers from β-radiation were performed with the 
software VARSKIN® Mod 2 (J S Durham, Pacific Nortwest Laboratory, 
USA). The VARSKIN code is based on a beta dose point kernel algorithm, 
averaged over an area of 1 cm2. The reliability of the code has been tested by 
independent users and has shown good agreement with Monte Carlo 
simulations (Sherbini et al. 2008), performed with the MCNP code for β 
endpoint energies from 0.3 to 2.3 MeV, thereby including 2.28 MeV, the 
endpoint energy of 90Y. The mean yield and fraction of absorbed dose from 
bremsstrahlung, as compared to electrons, were expected to be as low as 0.3-
0.4% and 0.1-0.2% (Stabin et al. 1994), respectively, and the bremsstrahlung 
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absorbed dose was therefore neglected. Technical details about the simulation 
procedure can be found in Paper I. 
3.2.2 Measurements on resected tissue surface 
Some resected tissue volumes were foiled with 0.4 mm transparent plastic, 
with similar shielding properties as polystyrene plastic, specified in the 
simulations. Thermoluminescent dosimeters (TLD), with a size of 3×3×1 
mm3, were taped with square side facing the outside of the foil, which was 
covering the tissue. For Pt 1, 10 TLDs were taped on the shortest side of a 
slice with a 1×2 cm2 cross-section area (See Paper I), containing tumour and 
NL tissue; for Pt 2, 15 TLDs were taped on tissue shaped as a spherical cap 
(See Paper I). The corresponding absorbed dose rates on tissue surface in the 
middle of surgery, representing the average absorbed dose rate during 
surgery, was calculated by decay correction (See Paper I). 
3.3 Radioactivity in resected tissue (II, III) 
3.3.1 Activity and microsphere detection 
Some resected tissue, from both patients, was machine sliced into sections, 
approximately 1 to 8 mm thick for Pt 1 and 1 to 2 mm thick for Pt 2.  
Autoradiography 
Every other slice was covered in double layers of 0.2-mm plastic film and 
exposed to autoradiography films (Amersham Hyperfilm® MP, GE 
Healthcare, Uppsala, Sweden) in cassettes (Pt 1: for 5 h, 5 days after surgery; 
Pt 2: for 2 h, 3 days after surgery). 
Gamma well counter measurements 
The remaining slices were punched into various sizes (diameters 3, 4, 6 and 8 
mm), with masses 8 to 422 mg for Pt 1 and 5 to 102 mg for Pt 2. Each punch 
biopsy was weighed and immersed in 1 ml formaldehyde (10 %), in plastic 
vials with an inner diameter of 9 mm and a wall thickness of 1 mm. The 
biopsy-specific activity was measured from bremsstrahlung, in an automatic 
gamma well counter (Wizard® 1480, PerkinElmer, Waltham, MA, USA), 
calibrated for known 90Y activity, with a relevant activity interval, in the 
same vial type and formaldehyde (10%) volume. The activity concentration 
at day of injection (and absorbed dose, assuming complete decay from day of 
injection) was calculated by decay correction (See Paper I for equation).  
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Microscopy 
A smaller sample, 6 punch biopsies (4 to 8 mm diameter) of NL from Pt 2, 
was sectioned, (10 serial sections per biopsy), 20 µm thick (Paper II). 
Another 16 NL punch biopsies was selected from Pt 2, for a more rigorous 
analysis of microsphere distributions, related to activity concentration. The 
punch biopsies of the larger sample were chosen, aiming for intra-sample 
mass homogeneity (6 to 8 mm diameter) and activity concentration 
heterogeneity (Paper III). The orientation of the sectioning was optimized for 
cluster tracking (transversal to vessels). Each biopsy was sectioned in 15 
sections, with thickness 30 µm. All biopsies were paraffin embedded before 
sectioning and stained with haematoxylin-eosin (Campbell et al. 2000).  
3.3.2 Analysis of tissue activity heterogeneity 
Macroscopic distribution 
Autoradiography was performed in order to obtain an overview of two-
dimensional pattern tendencies and degree of heterogeneity, which could be 
of complementary use in analysis of biopsy measurements with gamma well 
counter. As mapping of the exact locations of activity units (i.e. 
microspheres) over a large volume is very tedious, it was not feasible to 
perform rigorous spatial distribution statistics, e.g. by applying Ripley’s K 
function, describing cluster formation tendencies by measurements of 
average distance between signal points in relation to expected distance in a 
randomised Poisson (i.e. homogeneous) distribution, the latter not influenced 
by structural variations (Kiskowski, Hancock and Kenworthy 2009). The 
relative heterogeneity of the microsphere distribution was instead calculated 
in a straightforward way, by the coefficient of variation (CV) and the 
skewness (SK), by the adjusted Fisher-Pearson standardised moment 
coefficient (Doane and Seward 2013) (See Paper II for details).  
The intuitive approach was that a rapid decrease of CV and SK with 
increasing element size (biopsy mass), within mass-specific samples, would 
indicate a heterogeneous pattern larger than the element size, i.e. individual 
biopsy volumes (Pickett and Cadenasso 1995, Wu 2004, Lam and Quattrochi 
1992, King, Johnson and O'Neill 1991). A heterogeneous pattern, with a 
basic unit (patch) larger than the mean range of the β-radiation, would not be 
homogenised by crossfire effects. A heterogeneous pattern with a basic unit 
of the same size as the smallest mass group or smaller is expected to show 
little mass dependence for CV and SK and the variance found within all 
samples would probably be explained by a combination of stochastic effects 
and expected presence of systematic variance, i.e. tissue absorbed dose 
gradients on a much larger, detectable with external imaging methods. As 
different sized punch biopsies are collected in a similar geometrical fashion, 
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the suggested method is expected to reveal heterogeneous patterns on a 
moderate scale, also within a distribution that is affected by larger dose 
gradients and by stochastic variance, expected to cause similar variation 
within all samples. 
To strengthen the argument for this approach, the effect is demonstrated on 
the heterogeneous, but repetitive, idealised, non-randomised pattern, shown 
in Figure 2. The symbols ሾ∙ሿ,	ሾ൅ሿ and ሾ∗ሿ represent signal values 1, 4 and 16, 
respectively. The pattern size is 3×6 or 6×3, which means that if the signal is 
averaged within area elements of exactly size 3×6 (independent of 
orientation) or 6×6, there would be no variation (i.e. mean signal = 2.1; CV = 
0 and SK = undefinable). Even in the most consistently repetitive pattern, 
from a real sample, there will always be some stochastic variation (noise), but 
in this example, only the idealised pattern is considered. For small elements, 
high CV and SK are expected, rapidly decreasing with element size.  
In the nine samples described by the plots in Figure 3, each sample contains 
output from 64 equally-sized area elements (Figure 2B). The sampling is 
done, stepwise, (overlapping for sizes > 1) by letting each element cover an 
element-unique geometric space. This procedure is similar to down-sampling 
(Loew et al. 1980) an image with the nine shown different element areas used 
as masks. In the present example, overlapping of previous elements is 
allowed, in order to collect large enough samples from the limited pattern 
area of 10×10 square units.  
The first sample would therefore cover a total pattern area of 64 squares, the 
second 72, the third 80 etc., up to the entire pattern of 100 squares for the last 
sample, with elements 3×3 squares wide. As the total area investigated is 
considerably larger than the repetitive pattern, for all element sizes, and the 
samples are fairly large, the output is not expected to suffer from severe edge 
effects, or low representativeness, as compared to randomised spatial 
sampling within a larger area of the same repetitive pattern.  
Although the output values of signal averaging (not shown) are highly 
discretised, as a consequence of the lack of randomisation in the pattern, the 
trends for the distribution parameters are clear: both CV and SK decrease 
rapidly for small elements; the decrease is still present, but less dramatic, for 
larger elements. 
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Figure 2. A signal pattern is shown in (A); the signal values of 1, 4 and 16 are 
illustrated with the symbols [∙], [൅] and [∗], respectively. The repetitive pattern has 
the size 3×6 or 6×3 area units. Nine samples are gathered, containing 64 signal-
averaging elements per sample; each sample contains equally sized sample-unique 
area elements, one of the nine different area elements shown in (B). The 64 sample 
elements are uniquely distributed, with edges aligning the 10×10 square grid, but the 
separate elements within a sample are allowed to overlap geometrically; the entire 
samples cover 64 to 100 of the 100 squares in the pattern, with larger coverage for 
samples with larger element area size.    
 
 
 
 
  
 
 
A 
B 
Jonas Högberg 
33 
 
 
Figure 3. The plots show the distribution parameters for the samples described in 
Figure 2, specified for the element-size unique samples. The average of all samples, 
for their intrinsic mean signal per element (data not shown), is 2.04±0.03. Both CV 
[o] and SK [∗]) decrease non-linearly with element size; the decrease is more 
dramatic for smaller element sizes. 
 
Small-scale distribution  
The sections were investigated sequentially for single and aggregated 
microspheres, in order to track clusters distributed within the same 
artery/arteriole, through more than one section; a cluster was defined as two 
or more spheres with an approximate inter-sphere distance of 0.2 mm (i.e. no 
more than 8 sphere diameters) or less. The clusters were found as thin strings 
of single spheres or wider sphere conglomerates, either densely or sparsely 
packed (with one or more cross-sections of the same cluster lacking spheres). 
Due to chosen orientation, most clusters were sectioned trans-axially, but 
some clusters were distributed in a more diagonal fashion throughout the 
sections. 
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3.3.3 Simulation of absorbed dose (III) 
Simulations of small-scale absorbed dose distribution were performed, based 
on the microsphere distributions found in the 16 microscopically scrutinised 
punch biopsies, mentioned in section 3.3.1 (the smaller sample of 6 punch 
biopsies, studied with the simplified method, was not included). The 
simulations were performed by i) spatial randomization of activity loci from 
the microscopically registered sphere  distribution, containing single spheres 
and clusters, up to the activity measured sphere concentration (MAD, 
assuming CPE), ii) convolution of mentioned, semi-randomised, virtual 
activity volumes with a 90Y beta dose point kernel, according to Prestwich et 
al (Prestwich, Nunes and Kwok 1989), tuning the absorbed fractions for 
centremost voxels, according to Siegel and Stabin (Siegel and Stabin 1994) 
and iii) obtaining absorbed dose distributions, based on the sub-volume of 
each output matrix where the conditions for charged particle equilibrium 
(CPE) was fulfilled. A consequence of this was that MAD became directly 
coupled with activity concentration. The simulation process (i.e. 
technicalities) is described in further detail in Paper III. 
3.3.4 Statistics 
Median, mean ± standard deviation (mean ± SD), CV and SK were used to 
describe normally distributed continuous variables. Relationships were 
evaluated by linear regression, applying Ordinary Least Squares (OLS), to 
either the dependent variable data point set or its logarithmised data point set. 
Hypothesis tests (two-sided t-test) were performed, α = 0.05. 
3.4 Simulation of arterial tree model (IV) 
3.4.1 Microsphere distribution 
Microsphere distributions, with different MADs as end points, were used in 
an adapted version of the branching artery tree model described by Walrand 
et al (Walrand et al. 2014a) (See section 1.6). The adaption was made by 
introducing variability in the microsphere and artery diameters. The mean 
artery diameters were exponentially decreasing. Three variable parameters 
were optimised to obtain concordance between simulations and microsphere 
distributions: a combined artery coefficient of variation (ACV) parameter for 
the inner diameter of all artery generations throughout the virtual tree 
structure and the microsphere flow distribution at the nodes, the hepatic tree 
distribution volume (HDV) parameter, and the embolisation (EMB) 
parameter, that reduces the artery diameters. The model was tested against 
the measured sphere distribution in 16 biopsies with microsphere 
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“We don’t see things as they are, we see them as we are” 
 
-Anaïs Nin 
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4 RESULTS 
4.1 Pre-therapeutic imaging (I,II,III,IV) 
The planar imaging revealed low pulmonary shunting fractions of 3.0% (Pt 1) 
and 3.5% (Pt 2), and averaging voxel signal in the entire tumour and NL 
tissues by SPECT/CT, showed sufficiently high TNCs of 2.7 (Pt 1) and 3.8. 
Assuming complete in-vivo decay when performing calculations (i.e. without 
surgery) the prescribed activities (see section 3.1.2) were expected to result in 
the following total liver MADs: Pt 1: tumour: 59 Gy, NL: 22 Gy; Pt 2: 
tumour: 125 Gy, NL: 33 Gy. Du to resection, 9 days post-RE administration, 
the resected tissue would receive 90% of the above in-vivo absorbed dose. 
4.2 Surgery radiation exposure (I) 
Results of both simulations and measurements of absorbed dose rate to 
tumour tissue, including different number of glove layers (simulations) and 
with the actual radiation protection layer for TLD measurements are shown in 
Table 3. Considering TNCs of 2.7 and 3.8 (see section 4.1), the 
corresponding absorbed dose rate on NL tissue is expected to be, typically, < 
40% of mean absorbed dose rate on tumour tissue. 
4.3 Radioactivity in resected tissue (II,III) 
4.3.1 Autoradiography (II) 
Autoradiograms of resected tumour and NL tissue are shown in Figure 5. The 
patterns reveal a generally higher activity concentration in tumour than in 
NL. The patterns are inhomogeneous, with both aggregated areas (hot spots) 
and areas with limited activity concentration (cold spots). 
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Table 3. Simulations and measurements of decay-corrected absorbed dose 
rate levels on tumour tissue of Pt 1 and Pt 2, including radiation protection 
with gloves. Absorbed dose rate measurements on tumour tissue with TLDs 
are shown in the two rightmost columns; for Pt 1 a sample of 8 elements 
(TLD positions) and 15 elements for Pt 2. Each glove layer was simulated as 
0.2 mm polystyrene plastic. 
 Simulations (mSv h-1) 
Measurements 
Mean ± SD | Max 
(mSv h-1) 
Glove 
layers Pt 1 Pt 2 Pt 1 Pt 2 
0 53 65   
2 39 47 45±24 | 81 45±22 | 87 
3 32 40   
4 27 36   
 
4.3.2 NL tissue activity distributions 
Biopsies were gathered for both NL and tumour tissue. The total available 
number of tumour biopsies within narrow mass intervals was low (totally 25 
for Pt 1 and 41 for Pt 2, both samples with a wide mass range). As the main 
focus of this work is on NL tissue, the data shown here are from NL tissue 
only (For comparison with tumour data, see details in Paper II). For Pt 2, 
much NL tissue was available and substantial gathering of biopsies was 
feasible, as shown in Figure 5. The total number of NL punch biopsies from 
Pt 1 was 96 and the corresponding number from Pt 2 was 159. In Tables 4 
and 5, the distribution parameters for NL tissue from Pt 2 are shown (Table 4, 
adjacent to tumour; Table 5, far away from tumour). The distributions 
presented in Table 5 are also presented in distribution histograms in Figure 6, 
thereby facilitating the interpretation of the distribution parameters CV and 
SK, for the actual case. The decreasing CV and SK with increasing activity 
concentration is apparent in both Tables 4 and 5, as well as in Figure 6.  
 
 
  
 
 
 
Figure 5
tissue fr
liver tiss
D), the 
two sep
panels. 
collected
 
A 
C 
. Photographs
om Pt 1 and P
ue, outlined at
normal tissue w
arate sub-volu
The punch sa
 after autorad
 
 (A and C) an
t 2; for Pt 1 (A
 the top of the 
as dominant 
mes being tum
mples, explain
iography. 
 
41 
 
 
d correspondin
 and B), there a
images, the res
in the investiga
our is outline
ing the perfo
B
D
g autoradiogr
re only small 
t being tumour
ted sample; th
d at the right
ration of the 
Jonas H
 
 
ams (B and D)
regions of norm
. For Pt 2 (C a
e only part of 
most ends of 
tissue (C), w
ögberg 
 of 
al 
nd 
the 
the 
ere 
Small-Scale Absorbed Dose Modelling in Selective Internal Radiation Therapy 
42 
Table 4. Activity distributions in NL tissue adjacent to tumour of Pt 2; CV 
represents the coefficient of variation, m the mean mass of n tissue biopsies, 
Spheres/biopsy, the average number of spheres per biopsy, A/m the mean 
activity concentration and SK the skewness of the distribution 
 
Mass (mg) 
 
Small 
5 ≤ m ≤ 14 
 
Medium 
16 ≤ m ≤ 41 
 
Large 
43 ≤ m ≤ 102 
  
All 
5 ≤ m ≤ 102 
 
m (mg) 
 
n 
 
Spheres/biopsy 
 
A/m (Bq/mg) 
 
10 
 
26 
 
380 
 
1900 
 
27 
 
24 
 
920 
 
1700 
 
69 
 
25 
 
2300 
 
1700 
 
35 
 
75 
 
1200 
 
1700 
     
CV 
 
0.81 
 
0.58 
 
0.45 
 
0.64 
 
SK 1.8 1.2 0.69 1.9 
 
Table 5. Activity distributions in NL tissue far away from tumour of Pt 2; CV 
represents the coefficient of variation, m the mean mass of n tissue biopsies, 
Spheres/biopsy the average number of spheres per biopsy, A/m the mean 
activity concentration and SK the skewness of the distribution 
 
Mass (mg) 
 
Small 
6 ≤ m ≤ 14 
 
Medium 
15 ≤ m ≤ 39 
 
Large 
40 ≤ m ≤ 91 
  
All 
6 ≤ m ≤ 91 
 
 
m (mg) 
 
n 
 
Spheres/biopsy 
 
A/m (Bq/mg) 
 
10 
 
29 
 
300 
 
1500 
 
27 
 
26 
 
590 
 
1100 
 
66 
 
29 
 
1200 
 
900 
 
35 
 
84 
 
740 
 
1040 
     
CV 
 
1.4 
 
1.0 
 
0.63 
 
1.3 
 
SK 3.0 1.8 0.82 4.0 
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Figure 6. The CV of the activity concentration distribution is shrinking with 
increasing biopsy mass, within NL of Pt 2; (A) masses 6 to 14 mg, (B) masses 15 to 
39 mg and (C) masses 40 to 91 mg. All distributions are divided into 11 bars; note 
that this implies different bar widths. 
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4.3.3 NL tissue microsphere distributions 
The investigation of the smaller NL tissue sample of 60 sections, from six 
punch biopsies of Pt 2, revealed 240 locations with a total of 793 
microspheres; 154 (64%) of the locations were single spheres, representing 
only 19% of all spheres. 53% of all spheres were located within any of the 19 
largest clusters (7% of the locations), ranging from 8 to 59 spheres per cluster 
(see Paper II for detailed information). The investigation of the larger NL 
tissue sample of 240 sections, from 16 punch biopsies of Pt 2, revealed 3888 
spheres (152 single spheres and the remaining 3736 spheres in clusters of 
different size). The 3736 aggregated spheres were found within 277 clusters, 
many of them distributed throughout several sections and some throughout 
all 15 available biopsy-specific sections. Assuming CPE, the combined well 
counter- and scales-measured activity concentrations did correspond to the 
following MADs for the 16 biopsies: 8, 12, 17, 19, 21, 24, 29, 33, 38, 46, 48, 
54, 56, 59, 61 and 84 Gy. Clusters with different number of spheres per 
section are shown in Figure 7. Figure 8A shows the distribution of cluster 
sizes and Figure 8B illustrates the strong correlation between cluster size and 
number of spheres per section (i.e. larger clusters are found in PT 
arterioles/arteries with larger diameters). Figure 9 demonstrates the 
exponentially increasing maximum cluster size with increasing MAD. A 
general trend of increasing proportion of microspheres in increasingly larger 
clusters with increasing MAD was also apparent (See Paper III). 
Simulated absorbed dose distributions (III) 
Figure 10 shows how CV of the small-scale absorbed dose distribution 
increases linearly with increasing MAD. 
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Figure 8. (A) Histogram of cluster size and frequency. Clusters > 100 spheres per 
cluster are rare, but each of these clusters houses a large fraction of the total number 
of spheres; (B) The cross-section size is found to increase linearly with cluster sizes, 
especially for larger clusters, reflecting the tendency of finding larger clusters in 
larger arterioles/arteries. 
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Figure 9. The largest cluster size in each of the 16 biopsies and the corresponding 
trend line for exponential increase, from approximately 16 spheres per cluster at 10 
Gy to 400 spheres per cluster at 80 Gy. The cluster size levels increase exponentially 
with the mean absorbed dose in the biopsies.   
 
Figure 10. The CV of small-scale absorbed dose increasing with mean absorbed 
dose; the 16 separate absorbed dose simulations were based on cluster distribution 
patterns of the microscopic sub-samples, but added up to the mean absorbed dose 
within the specific biopsy, the mean absorbed dose based on activity measurements 
with gamma well chamber, assuming charged particle equilibrium. The resulting 
graph shows a linear increase in CV of the absorbed dose, with biopsy mean 
absorbed dose. 
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4.4 Arterial tree simulations (IV) 
4.4.1 Microsphere distribution 
Figure 11A shows the distributions from the 16 biopsies, with high frequency 
for small clusters but the low frequency regions contain several hundreds of 
spheres per cluster. The cluster deposits are mainly found within higher 
artery generations (Figure 11B) and less frequently within larger arteries 
(lower generations). However, the largest clusters were always located in the 
largest arteries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The distribution of the spheres in 16 biopsies, with a mean concentration 
of 14 spheres/mg. A) The distribution of number of spheres vs. spheres per cluster. B) 
The distribution of sphere clusters in the different artery generations. The spheres 
were found in artery and arteriole diameters that correspond to the artery 
generations 13 to 19. Microspheres which were considered to be located in arteries 
and arterioles with diameters less than the microspheres were collectivly placed in 
the 19th generation. This was performed due to difficulties to accuratly determine the 
inner diameter of  small vessels. 
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For the parameter values: ACV=0.35, HDV=50 cm3 and EMB=6 µm, 
harmony was found between simulated and measured cumulative frequency 
of the microsphere distribution versus both spheres per cluster and artery 
generation for the 16 biopsies (R2>0.99) (Figure 12A-B). These parameter 
values also generated similar agreement between simulated and measured CV 
for different sized samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Comparision of simulations and measured sphere distributions for sphere 
concentration of 14 spheres/mg. A) The cumulative cluster frequency vs. spheres per 
cluster, and B) the cumulative cluster frequency vs. artery generation, for the 
measured biopsies [∗]and simulation (line) (r2>0.99). C) Simulation of the sphere 
concentration distribution in 10 (black line), 27 (black dotted line) and 66 mg (grey 
line) samples revealed more normally distributed frequency curves and decreasing 
CV for higher microsphere concentrations. 
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Figure 12C shows the simulated sphere distribution for three sample sizes; 
the CV for the 10, 27 and 66 mg samples is 1.4, 1.0 and 0.56, respectively. 
Corresponding CV for the punch biopsy measurements was 1.4, 1.0 and 0.63, 
respectively (See Table 5). 
Figure 13 shows the cumulative frequency of the microsphere distribution for 
the three microsphere-concentrations and the concordance with the best fit to 
the simulations (R2>0.98). In comparison to the mean sphere concentration 
(14 spheres mg-1) ACV and EMB decreased to 0.20 and 2 µm, respectively, 
for lower sphere concentration (4.6 spheres mg-1) and HDV increased to 130 
cm3. For higher sphere concentration (28 spheres mg-1) the opposite was 
obtained; the optimal parameter values were then: ACV 0.46, HDV 22 cm3 
and EMB 8 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
The cumulative cluster frequency versus A) spheres per cluster and B) artery 
generation for the measured biopsies∗[+,*,×] and simulation [line]. Simulation of 
sphere distribution for the different sphere concentrations resulted in different 
parameter values. The best fit to the mean biopsy sphere concentrations of 4.6 (+ and 
dotted line), 14 (∗ and black line), and 28 (× and grey line) spheres/mg was obtained 
for: ACV of 0.26, 0.35, and 0.46, respectively; HDV of 130, 50 and 22 cm3, 
respectively; EMB of 0, 6 and 8 µm, respectively; (r2>0.98). 
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“Clear thinking requires courage rather than intelligence” 
 
-Thomas Szasz 
 
 
Small-Scale Absorbed Dose Modelling in Selective Internal Radiation Therapy 
54 
  
Jonas Högberg 
55 
5 DISCUSSION 
5.1 Surgery radiation exposure (I) 
Simulations for Pt 1 and Pt 2 showed expected mean absorbed dose rates 
(with 0.4 mm shielding plastic material) of 39 mSv h-1 and 47 mSv h-1, 
respectively. The corresponding measurements on resected tumour tissue for 
Pt 1 and Pt 2 showed mean absorbed dose rates of 45 mSv h-1 for both 
patients. The simulations thus underestimate the absorbed dose rate for Pt 1 (-
13%) and overestimate the absorbed dose rate for Pt 2 (+4%). The deflections 
are not severe, however. The maximum absorbed dose rate on the tumour 
surface was about twice the simulated absorbed dose rate, assuming 
homogeneous activity distribution. As the surgeon is expected to move the 
fingers during surgery, the mean absorbed dose rate to the surgeon’s fingers 
during complete surgery is expected to be closer to the mean than to the 
maximum absorbed dose rate. 
5.2 NL tissue activity distributions (II,III) 
5.2.1 Macroscopic distribution 
The acquired autoradiograms, showing non-uniform distributions and 
different-sized aggregations (hot spots) and areas lacking activity (cold 
spots), showed indications of a heterogeneous three-dimensional distribution 
of both activity and absorbed dose. This is in accordance with various 
previous reports, on distributions in human and animal tissue (Kennedy et al. 
2004, Burton et al. 1989, Campbell et al. 2000, Roberson et al. 1992, Pillai et 
al. 1991), described in section 1.4.4. The mentioned studies were, however, 
either concentrated on tumour tissue or on limited volumes of NL tissue. 
Furthermore, no systematic three-dimensional analysis of microsphere or 
absorbed dose distributions was performed on NL tissue.  
The advantage of investigating radioactive tissue (Paper II) was that samples 
from a relatively large volume could be analysed, in a rapid and feasible way. 
Apart from the mentioned overview with autoradiography, activity 
measurements of tissue volumes made it possible to obtain a better three-
dimensional description of the distribution. Furthermore, it was possible to 
show whether the heterogeneous activity was distributed in a larger repetitive 
pattern, than could be homogenised considerably by cross-fire or not. 
According to assumptions in Section 1.4.4, extensive heterogeneity will 
occur if the repetitive pattern is larger than 2.5×2.5×2.5 mm3 = 16 mm3 (i.e. a 
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mass of 16 mg NL tissue). The heterogeneity pattern was investigated by 
calculation of CV and SK for the activity concentration; the assumption was 
that both CV and SK would decrease considerably with increasing punch 
biopsy mass, should the heterogeneity pattern be the same size or larger than 
the individual punch biopsies within the biopsy group with the largest punch 
biopsy mass. As mentioned in Paper II, it was hard to apply this analysis 
method to Pt 1, with no consistent trends for NL tissue CV or SK, as the 
number of samples was small in combination with a large variation in biopsy 
mass for this patient. The biopsy samples of Pt 2, on the other hand, showed 
clear trends of striking decrease of both CV and SK with biopsy mass. As 
different-sized biopsies were distributed in a similar manner on a large scale, 
variance related to large-scale activity concentration gradients is expected to 
be present within all the compared biopsy mass groups. In line with the 
example presented in Section 3.3.2, the decreasing CV and SK with 
increasing mass are therefore expected to be explained by heterogeneity on a 
scale referred to in this work as on a macroscopic scale (2.5–20 mm), rather 
than on a large scale (> 2 cm). 
5.2.2 Small-scale distribution 
The smaller sample of punch biopsies investigated by light microscopy 
(Paper II) provided indications of cluster gatherings and the simplified 
method used revealed cluster sizes < 60 spheres per cluster. In order to 
investigate the occurence of even larger clusters and the possible relation 
between cluster size and MAD, better sectioning orientation (transversal to 
vessels) was applied, larger total volumes of each punch sample were 
scrutinised and biopsies spanning over a wider range of MAD were collected 
(Paper III). The latter study revealed 11 clusters > 60 spheres per cluster, and 
40% of the total number of 3888 spheres found, within totally 240 sections of 
16 punch biopsies, were lodged within these 11 very large clusters, the three 
largest clusters (i.e. 174, 306 and 453 spheres per cluster) found within the 
three biopsies with the highest MAD, i.e. 59, 61 and 84 Gy. 
Figures 8B and 9 show that individual size of the 277 found clusters is 
strongly correlated with arterial diameter (for further details, see Paper III) 
and that the abundance of larger clusters (in larger arterioles/arteries) is 
increasing exponentially with increasing MAD. This implies that a high 
MAD often is a direct consequence of the occurence of at least one very large 
or several smaller clusters. 
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5.3 Simulated absorbed dose (III) 
The simulations of absorbed dose distributions within the 16 simulated sub-
volumes, based on microsphere distributions within the punch biopsies, 
showed that the intrinsic non-uniformity in microsphere distribution was not 
homogenised, to any larger extent, by cross-fire. The increasing CV of small-
scale absorbed dose with MAD demonstrates a direct consequence of the 
exponentially increasing cluster sizes with activity concentration, discussed 
in section 5.2.2. As showed by the increasing CV with activity concentration 
(or MAD, when assuming CPE) it is expected that the absorbed dose 
distribution within sub-volumes with a moderate or high MAD (the absorbed 
dose interval being radiobiologically interesting, when investigating 
heterogeneity effects), is influenced by strong absorbed dose gradients, and 
caused by occurrence of large clusters.  
5.4 Arterial tree model simulations (IV) 
5.4.1 Microsphere distribution 
The simulation of microsphere distributions resulted in sphere aggregations 
throughout different artery generations, implying single spheres and smaller 
conglomerates of spheres in higher generations (i.e. with smaller diameter) 
and larger clusters in lower artery generations (i.e. with larger diameter). 
These simulations showed the influence of geometric variance, both 
regarding diameters within artery generations and in microsphere diameters. 
For the highest concentration of microspheres (28 microspheres/mg), the 
simulations indicated an even higher tendency for large clusters than 
observed in biopsies. However, it is possible that the total thickness of the 
sequential sections (15 sections, 450 µm in total) was not large enough to 
determine the complete extent of some large (50-100 microspheres/cluster) or 
very large (> 100 microspheres/cluster) clusters.  
In the proposed model, the microspheres were assumed to be transported 
through the hepatic tree until entrapment, due to spatial constraints in the 
vessels. Furthermore, it was assumed that the variations may be described by 
the ACV parameter, which is normally distributed and inherently includes 
specific factors that influence the entrapment probabilities of the 
microspheres to various degrees. The simulations showed that ACV increases 
with increasing microsphere density, perhaps due to the random trapping 
process alone. Alternatively, this observation may reflect that the native 
artery tree structure deviates more from the simplified dichotomous 
bifurcation model in terms of the total variation. In addition, the used 
dichotomous bifurcation model returned an HDV of 130 cm3 for the low 
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concentration of microspheres and 20 cm3 for high concentration, indicating 
that the model does not effectively capture the whole liver. This is 
understandable, however, since the number of arteries generated by the 
dichotomous bifurcation model is far lower than the estimated number of 
arteries in a native liver (Debbaut et al. 2014). A decreased HDV for high 
microsphere concentrations is equivalent to an increased number of 
microsphere-accessible pathways per liver volume, and hence the number of 
arteries approaches the number found in the native polyfurcation model of the 
liver. Increasing the microsphere concentration decreased the HDV value and 
increased the EMB value, of which the latter is used for modelling 
embolisation when vessels accumulate microspheres.  
5.4.2 Absorbed dose distribution 
The simulated absorbed dose distributions showed geometric patterns with 
CV for absorbed dose increasing with increasing MAD, implying large 
absorbed dose gradients in regions with higher MAD, in agreement with 
assumptions originating from the biopsy investigations. Figure 14D-F 
illustrates that the occurrence of large clusters in high MAD regions has a 
considerable impact, not only on absorbed dose variation for samples divided 
into voxels. The heterogeneity remains for sub-layer MAD, i.e. when sub-
layers of the total MAD volume are considered sample elements.  
5.5 Clinical implications (II,III,IV) 
Cremonesi et al (Cremonesi et al. 2014) recently pointed out challenges in 
quantification of radiobiological risks in RE treatment and that threshold 
absorbed doses avoiding NL toxicity are not conclusively defined. They 
explained that the reason for this is lack of methodological differentiation of 
tumour and NL tissue absorbed dose, both for glass spheres and for the most 
common resin sphere administration method, i.e. the Body Surface Area 
(BSA) method. Furthermore, detailed dosimetric follow-up studies targeting 
NL toxicity (Gulec et al. 2007, Lau et al. 1998) and NTCP modelling (Chiesa 
et al. 2012, Strigari et al. 2010, Walrand et al. 2014b) are rare (See section 
1.4.3). 
Absorbed dose heterogeneity on a large scale has been reported for both glass 
and resin spheres, using various imaging methods (Kao et al. 2013a, 
D'Arienzo et al. 2012, D'Arienzo et al. 2013, Sarfaraz et al. 2003, Sarfaraz et 
al. 2004). In the present thesis, heterogeneity on a macroscopic scale (larger 
than the mean range of the 90Y β-radiation) was studied and the heterogeneity 
was found to be on an even larger scale, though perhaps not on a large 
enough scale for imaging, implying the presence of absorbed dose variations 
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that cannot be detected with non-invasive imaging methods. The scale is too 
large, however, for any considerable cross-fire homogenisation effects to 
influence the absorbed dose heterogeneity pattern. 
Dosimetry on a small and even microscopic level is important, however, in 
order to create more complete and reliable models, capable of describing 
radiobiological risks. The reason for this is that microscopic or small-scale 
heterogeneity, combined with macroscopic heterogeneity, will reveal the total 
potential for radiobiological sparing of parenchyma, as some fractions of the 
biopsies receiving a high absorbed dose on the scale of several millimetres 
(macroscopically), could still contain sub-volumes of lower absorbed dose.  
As mentioned in sections 1.4.4 and 1.6, some authors have described small-
scale microsphere and absorbed dose distributions within NL tissue, both by 
investigations of explanted liver tissue (Fox et al. 1991, Burton et al. 1989) 
and by simulations (Gulec et al. 2010, Walrand et al. 2014a), demonstrating 
microsphere concentration dependent heterogeneity. The tissue volumes 
investigated have been small, making it hard to evaluate the 
representativeness of their results. The computer model by Gulec et al, 
assuming homogeneous microsphere distribution, demonstrated structural 
differences in absorbed dose, i.e. when comparing different structures. The 
absorbed doses did, however, not vary within the total volume of the same 
structures, i.e. no variation in absorbed dose was found within PT, the central 
veins or within the parenchyma. This is plausible, as no distributional or 
stochastic variations were introduced in their model. The model by Walrand 
et al, including some distribution heterogeneity, demonstrated absorbed dose 
heterogeneity only for distributions with a low total number of spheres (i.e. 
typically for glass sphere RE). The NL tissue and simulation investigations, 
accounted for in the present work, may nuance this assumption and possibly 
incentivise new approaches for NTCP modelling in RE therapy.  
Although some sub-regions of biopsies with high MAD suffer extreme 
absorbed dose levels, other sub-regions may experience radiobiologically 
tolerable absorbed dose levels. The total biological outcome of this 
phenomenon is uncertain, however, as embolisation by large microsphere 
aggregations may either induce sub-regions of low absorbed dose and 
beneficial hypoxia (radioresistance) or cause cell death (necrosis) by 
extensive hypoxia (Lagerlöf et al. 2014). The latter effect would in that case 
be explained by the combination of embolisation effects in the artery and 
radiobiologically obstructive effects on the vein/venule within the same PT, 
thereby halting practically all blood supply to the parenchyma sub-volume. 
The size of such regions would depend on cluster size, as larger clusters are 
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located in lower artery generations, i.e. with a larger diameter, thus supplying 
blood to a larger NL volume.  
The decreased HDV for high microsphere concentrations makes the present 
model useful for small-scale analysis, but macro-analysis of microsphere 
distributions in specific liver segments with volumes as low as 20 cm3 should 
include data from imaging methods such as SPECT or positron emission 
tomography (See section 1.5.2). The combined knowledge of large-scale 
(from imaging) and small-scale distributions derived from the present work 
may be beneficial in improving NTCP models for RE. 
Even though healthy parts of liver parenchyma are expected to be similar 
within and between patients (see section 1.1.1), the inclusion of more patients 
and larger tissue elements (more sections per biopsy) and samples (more 
elements per sample) would assure a better representativeness of the 
presented results. It is probable that inclusion of more data would modify the 
model input to some extent, e.g. by encounters of even larger clusters than 
the ones found in the present investigations and/or an otherwise modified 
distribution pattern, hence prompting adaptions of input parameters for the 
arterial tree model. 
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“There is no sense in being precise when you do not even know what you are 
talking about” 
 
-John von Neumann 
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6 CONCLUSIONS 
6.1 Surgery radiation exposure (I) 
The comparison of simulations to TLD measurements shows Varskin Mod 2 
to be a promising tool in predicting average tumour surface absorbed dose 
rates. A surgeon performing liver surgery on patients still radioactive from 
RE treatment should be a classified (Category A) radiation worker. Pre-
surgical simulations based on the planned procedure are recommended. It is 
also recommended that surgeons wear finger dosimeters. Given the simulated 
and measured absorbed dose rates, it is expected that a surgeon can perform 
about three surgeries of the reported kind, before approaching the annual 
absorbed dose limit to the hands (Directive 1996). 
6.2 Microsphere distribution (II,III,IV) 
6.2.1 Macroscopic distribution (II) 
The trends of decreasing CV and SK with increasing biopsy mass 
demonstrate that a macroscopic heterogeneous pattern is expected to be 
present, within NL, on a relevant geometric scale, considering the mean 
range of the 90Y β-radiation spectrum. The method of measuring absorbed 
dose distribution on a sample of punch biopsies is a quick and feasible 
method in order to describe ex-vivo macroscopic absorbed dose distribution. 
The method further demonstrates that autoradiography may be used for a 
two-dimensional overview of activity distribution, but the range of the β-
radiation makes the punch biopsy measurements more reliable for a rigorous 
evaluation of absorbed dose distribution.  
6.2.2 Small-scale distribution (II,III,IV) 
Microsphere cluster aggregations and cluster size increased exponentially 
with microsphere concentration. A strong relation was found between cluster 
size and artery cross-section diameter. This indicates increasing heterogeneity 
in terms of an increased variation in activity concentration within individual 
punch biopsies, with increasing biopsy MAD. The investigated geometric 
heterogeneity scale, i.e. > 16 mm3, is expected to be large enough for the 
demonstrated heterogeneity in activity distribution to cause absorbed dose 
non-uniformity within individual biopsies.  
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6.2.3 Simulated distribution (IV) 
The simulations of microsphere distributions resulted in cluster aggregations 
in different artery generations. Most microspheres were found within the 17th 
and 18th generation, consistent with a large number of mid-size and some 
larger clusters, in agreement with the microsphere aggregations found in 
punch biopsy sections. The results demonstrate that simulations from a 
dichotomous bifurcation model of the hepatic tree agree with microsphere 
distributions measured in liver samples, at least within NL sub-volumes. As 
mentioned in section 1.6, the dichotomous bifurcation artery tree is, however, 
a simplified model of a native hepatic artery tree, explaining the diminished 
small-scale variations with increasing simulated volume. The present model 
should therefore be limited to simulations within a limited fraction of the 
total NL parenchyma, particularly when the end point is a relatively high 
MAD. 
6.3 Absorbed dose distribution (III,IV) 
CV of absorbed dose increased with MAD, implying considerate absorbed 
dose heterogeneity, explained by increased fraction of spheres found in 
clusters and increased occurrence of larger clusters with increasing sphere 
concentration (or MAD, assuming CPE). The consequence of this was strong 
absorbed dose gradients within NL tissue within moderate and high MAD 
sub-volumes.  
6.4 Clinical implications (II,III,IV) 
The results reported in the present thesis, with large cluster lodgings outside 
the highest generations (i.e. outside the terminal, thinnest, arterioles) of the 
hepatic arterial tree, both as found in biopsies and by simulations, resulting in 
considerable absorbed dose non-uniformity, may challenge the hypotheses of 
limited absorbed dose heterogeneity for resin sphere RE. Strong absorbed 
dose gradients within individual biopsies will result in a systematic absorbed 
dose inhomogeneity, which may be beneficial for both parenchyma and other 
critical structures, with sub-volumes receiving a high absorbed dose, such as 
the PT. The decreased HDV for high microsphere concentrations makes our 
model useful for small-scale analysis, but macro-analysis of microsphere 
distributions in specific liver segments with volumes as low as 20 cm3 should 
include large-scale data. Therefore, imaging via SPECT/CT and PET/CT in 
combination with small-scale modelling may enable the use of small-scale 
dosimetry to determine SIRT tolerability and NTCP modelling. The total 
biologic outcome of large clusters should, however, be examined further, in 
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order to determine if the low absorbed dose for high MAD sub-regions is 
beneficial or if these sub-regions will suffer fatal consequences of extensive 
hypoxia leading to necrosis, caused by the combination of embolisation 
effects and the potentially radiobiologically obstructive influence on nearby 
portal venules/veins. 
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“The future is no more uncertain than the present” 
 
-Walter Whitman 
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7 FUTURE PERSPECTIVES 
The papers presented in this thesis have, by providing new information about 
microsphere and absorbed dose distributions in RE, opened up for better 
radiobiological modelling and optimisation of administration methods. 
It would be of clinical value to simulate the influence of variation of physical 
parameters such as microsphere diameter, total number of injected spheres, 
activity per sphere and also radionuclide and study how this may change the 
sphere and absorbed dose distribution parameters, e.g. CV and SK. 
The distribution parameters should be verified by inclusion of more tissue 
data, hence possibly prompting adaptions of input parameters for the arterial 
tree model. 
Furthermore, comparison of biomarker expressions (Guha and Kavanagh 
2011) at different distance to microsphere aggregations of different size, 
therefore depending on absorbed dose and structural sensitivity, would be 
valuable input, in order to explain toxicity mechanisms. 
It is also possible that tumour modelling (Lagerlöf et al. 2014) may provide 
possible application of the arterial tree model to tumour regions, with less 
adaptions for smaller tumours, as the morphology and vascularisation of such 
tumours are expected to be more similar to NL tissue than the more 
amorphous structure and chaotic vascularisation present in larger tumours 
(Milross et al. 1997).  
Finally, it would be of interest to simulate the influence of embolisation and 
radiobiological effects caused by large clusters. The aim would be to 
distinguish i) benefits of sub-regional low absorbed dose and radiation 
insensitivity caused by limited hypoxia from ii) too high a degree of hypoxia, 
leading to cell death (necrosis) within NL tissue, induced by the combination 
of embolisation effects and obstructive radiobiological damages to 
venules/veins within the PTs containing large microsphere clusters. 
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“… people will forget what you said, people will forget what you did, but 
people will never forget how you made them feel” 
 
-Maya Angelou 
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